News headlines about ACADIA Pharmaceuticals (NASDAQ:ACAD) have been trending somewhat positive on Friday, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ACADIA Pharmaceuticals earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.0341317405821 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern’s rankings:
A number of analysts have recently issued reports on ACAD shares. Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $50.00 price target (up previously from $48.00) on shares of ACADIA Pharmaceuticals in a research report on Monday, October 2nd. Goldman Sachs Group reiterated a “neutral” rating and set a $45.00 price target on shares of ACADIA Pharmaceuticals in a research report on Friday, October 6th. Leerink Swann reiterated a “market perform” rating on shares of ACADIA Pharmaceuticals in a research report on Monday, October 9th. Zacks Investment Research downgraded ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $49.00 price target on shares of ACADIA Pharmaceuticals in a research report on Sunday, September 17th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the company. ACADIA Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $48.86.
Shares of ACADIA Pharmaceuticals (NASDAQ ACAD) opened at $27.90 on Friday. The firm has a market capitalization of $3,410.00, a P/E ratio of -11.34 and a beta of 3.79. ACADIA Pharmaceuticals has a 12-month low of $25.06 and a 12-month high of $41.20.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.10. The company had revenue of $35.58 million during the quarter, compared to the consensus estimate of $32.03 million. ACADIA Pharmaceuticals had a negative return on equity of 67.68% and a negative net margin of 320.71%. ACADIA Pharmaceuticals’s quarterly revenue was up 571.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.61) EPS. equities analysts forecast that ACADIA Pharmaceuticals will post -2.41 earnings per share for the current year.
In other ACADIA Pharmaceuticals news, EVP Glenn Baity sold 74,321 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $30.14, for a total value of $2,240,034.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Laura Brege sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $30.06, for a total value of $751,500.00. Following the completion of the sale, the director now owns 15,000 shares of the company’s stock, valued at approximately $450,900. The disclosure for this sale can be found here. Insiders own 22.25% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/01/12/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-acadia-pharmaceuticals-acad-stock-price.html.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.